Azilect and Zelapar will be out for Parkinson's later this year

July 2006

Azilect and Zelapar will be out for Parkinson's later this year.

Azilect (rasagiline) is an MAO-B inhibitor similar to selegiline. It works by blocking the breakdown of dopamine.

Azilect can be used as initial therapy...to improve symptoms in patients with early Parkinson's.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote